Discovery and characterization of orally bioavailable 4-chloro-6-fluoroisophthalamides as covalent PPARG inverse-agonists
Open Access
- 13 December 2022
- journal article
- research article
- Published by Elsevier in Bioorganic & Medicinal Chemistry
- Vol. 78, 117130
Abstract
No abstract availableKeywords
This publication has 30 references indexed in Scilit:
- JLigand: a graphical tool for the CCP4 template-restraint libraryActa Crystallographica Section D Structural Biology, 2012
- REFMAC5 for the refinement of macromolecular crystal structuresActa Crystallographica Section D Structural Biology, 2011
- Features and development of CootActa Crystallographica Section D Structural Biology, 2010
- XDSActa Crystallographica Section D Structural Biology, 2010
- Structure of the intact PPAR-γ–RXR-α nuclear receptor complex on DNANature, 2008
- Phasercrystallographic softwareJournal of Applied Crystallography, 2007
- GW9662, a potent antagonist of PPARγ, inhibits growth of breast tumour cells and promotes the anticancer effects of the PPARγ agonist rosiglitazone, independently of PPARγ activationBritish Journal of Pharmacology, 2004
- Variance-modeled posterior inference of microarray data: detecting gene-expression changes in 3T3-L1 adipocytesBioinformatics, 2004
- Transcription coactivator TRAP220 is required for PPARγ2-stimulated adipogenesisNature, 2002
- Hepatic clearance of drugs. I. Theoretical considerations of a “well-stirred” model and a “parallel tube” model. Influence of hepatic blood flow, plasma and blood cell binding, and the hepatocellular enzymatic activity on hepatic drug clearanceJournal of Pharmacokinetics and Biopharmaceutics, 1977